BU’s Infectious Disease Lab Receives City Approval for Research
The National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University, a NEC member, received approval from the Boston Public Health Commission (BPHC) to research rare, yet life-threatening infectious diseases. The BPHC approval is the final government agency approval required for the lab to perform research at Biosafety Level 4 (BSL-4), the strictest level of safety regulations set by the federal government.
This authorization will allow BU researchers to work on developing vaccines for such deadly viruses as Ebola and Marburg. There are eleven labs across North America approved to work with BSL-4 substances and BU is one of two universities with such authorization. The lab is under constant scrutiny to ensure they are in accordance with security standards and all of their data is available to the public.
“As we have seen over the past several years, we are all vulnerable to potentially devastating infectious diseases that may have originated halfway across the globe,” says Gloria Waters, BU Vice President and Associate Provost for Research. “With the opening of the NEIDL’s BSL-4 lab, BU is poised to establish itself as a national leader in fighting microbial systems and infectious diseases. The work that will be carried out here will bring benefit and relief in the form of vaccines, treatments, and cures to people in Boston, the United States, and around the world.”
The New England Council congratulates Boston University on their BSL-4 certification and wishes them much success in creating vaccines for infectious diseases. Read more in BU’s release.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022